Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy
Authors
Keywords
-
Journal
Personalized Medicine
Volume 12, Issue 3, Pages 199-207
Publisher
Future Medicine Ltd
Online
2015-06-05
DOI
10.2217/pme.14.82
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addressing phenoconversion: the Achilles' heel of personalized medicine
- (2015) Rashmi R. Shah et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity
- (2014) K. E. Burns et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization
- (2014) J. Hicks et al. CURRENT DRUG METABOLISM
- Adverse drug reactions induced by valproic acid
- (2013) Radu M. Nanau et al. CLINICAL BIOCHEMISTRY
- Valproic acid pathway
- (2013) Yogita Ghodke-Puranik et al. Pharmacogenetics and Genomics
- Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures
- (2013) Irem Fatma Uludag et al. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
- Effects of UGT1A6, UGT2B7, and CYP2C9 Genotypes on Plasma Concentrations of Valproic Acid in Chinese Children with Epilepsy
- (2012) Yingjie Guo et al. Drug Metabolism and Pharmacokinetics
- A meta-analysis of pro-inflammatory cytokines in the plasma of epileptic patients with recent seizure
- (2012) Nian Yu et al. NEUROSCIENCE LETTERS
- Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development
- (2011) Kouichi Kurose et al. Drug Metabolism and Pharmacokinetics
- LC–MS/MS method for simultaneous determination of valproic acid and major metabolites in human plasma
- (2011) Shouhong Gao et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients
- (2010) Lan Tan et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Variability in drug metabolizing enzyme activity in HIV-infected patients
- (2010) Amanda E. Jones et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Molecular and Therapeutic Potential and Toxicity of Valproic Acid
- (2010) Sébastien Chateauvieux et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients
- (2010) Noushin Amini-Shirazi et al. TOXICOLOGY MECHANISMS AND METHODS
- Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
- (2008) Ulrich M. Zanger et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
- (2008) N A Helsby et al. BRITISH JOURNAL OF CANCER
- Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review
- (2008) M. F. B. Silva et al. JOURNAL OF INHERITED METABOLIC DISEASE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started